Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo

Multidrug resistance (MDR) is the major cause of chemotherapy failure, which is usually caused by the overexpression of ATP-binding cassette (ABC) transporters such as ABCB1 and ABCG2. To date, no MDR modulator has been clinically approved. Here, we found that lazertinib (YH25448; a novel third-gene...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yingfang Fan, Tian Tao, Zhixing Guo, Kenneth Kin Wah To, Da Chen, Shaocong Wu, Chuan Yang, Jinsui Li, Min Luo, Fang Wang, Liwu Fu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2022-03-01
Edice:	Molecular Therapy: Oncolytics
Témata:	multidrug resistance ABCB1 ABCG2 cancer lazertinib EGFR
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2372770522000237
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!